Compare Honeywell International Inc (HON) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs IDEXX Laboratories, Inc. — how do they compare? Honeywell International Inc trades at $228.55 (market cap $71.66B), while IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B). The key difference: Honeywell International Inc is the larger of the two by market cap, and Honeywell International Inc pays a 4.21% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| HON | IDXX | |
|---|---|---|
Market Cap | $71.66B | $44.48B |
Sector | Industrials | Health |
52-Week High | $248.04 | $766.68 |
52-Week Low | $188.14 | $520.87 |
Enterprise Value | $96.01B | $45.38B |
Dividend Yield | 4.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $225.78, up 0.34% with a bullish technical signal and strong institutional support. The company maintains solid fundamentals with a 10.89% net margin and 26.41% ROE, though recent earnings show mixed trends with Q1 2026 beating expectations but full-year 2026 guidance indicating potential decline. Recent developments include the completion of a £1.325 billion acquisition and a 2:1 reverse stock split.
The outlook remains positive with analyst consensus favoring Buy ratings (65.52%) and a $368.55 price target representing significant upside. Key risks include execution challenges post-spinoffs and margin pressure, while opportunities lie in automation growth and strategic acquisitions. The stock presents a balanced risk-reward profile for long-term investors.
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
